Evogene Ltd. (EVGN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
EVGN currently has 9.89M outstanding shares. with significant dilution risk as 68.6M authorized shares could dilute existing holders by 693.8%. The company has significantly diluted shareholders by 67.98% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 26, 2026 |
POS AM filing: This prospectus relates to the resale of ordinary shares by the selling shareholder, including ordinary shares issued or issuable pursuant to the exercise of ordinary warrants. |
9.9M | 69M |
| Sep 30, 2025 |
POS AM filing: This POS AM filing relates to the offering of ordinary shares underlying Series A and Series B warrants issued in a private placement on August 26, 2024. |
8.7M | 70M |
| Mar 28, 2025 |
POS AM filing: This is a POS AM filing providing information on the indemnification of directors and officers, details of ordinary shares offered by the selling shareholder via warrants, and the use of proceeds. |
6.7M | 72M |
| Mar 27, 2025 |
20-F filing | 6.5M shares outstanding |
6.5M | 75M |
| Sep 19, 2024 |
F-1 filing: This F-1 filing includes information on ordinary shares offered by the Selling Shareholder, which are the shares underlying Series A and Series B warrants issued in a private placement on August 26, 2024. The warrants have an exercise price of $3.55 per share and are exercisable immediately upon issuance. |
5.4M | 77M |
| Mar 28, 2024 |
20-F filing | 50.6M shares outstanding |
51M | 28M |
| Mar 01, 2024 |
F-3 filing: Evogene Ltd. is filing an F-3 form to offer up to $200,000,000 of Ordinary Shares, Warrants, Rights and/or Units. |
50M | 29M |
| Mar 30, 2023 |
20-F filing | 41.3M shares outstanding |
41M | 37M |
| Mar 31, 2022 |
20-F filing | 41.2M shares outstanding |
41M | 37M |
| Apr 02, 2021 |
20-F filing | 35.6M shares outstanding |
36M | 43M |
| Feb 19, 2021 |
F-3 filing: Evogene Ltd. may offer, issue and sell from time to time, in one or more offerings, up to $200,000,000, in the aggregate, of our ordinary shares, warrants to purchase ordinary shares, rights and units comprised of, or other combinations of, the foregoing securities. |
40M | 38M |
| Jul 31, 2020 |
F-3 filing: Evogene Ltd. may offer, issue and sell from time to time, in one or more offerings, up to $50,000,000, in the aggregate, of its ordinary shares, warrants to purchase ordinary shares, rights and units comprised of, or other combinations of, the foregoing securities. |
24M | 49M |
| Apr 27, 2020 |
20-F filing | 25.8M shares outstanding |
26M | 0 |